# Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

> **NCT04724226** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 34 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Camrelizumab; Apatinib

## Key facts

- **NCT ID:** NCT04724226
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04724226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04724226, "Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04724226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*